AteloGene® Local Use - Cosmo Bio Co.,Ltd.

Antibodies

>

AteloGene® Local Use

Catalog No.: KOU-1392
Size: 1KIT
[For 10 times of administration to mice]
Price: ¥65000
$867
catalog info: Catalog 2012-p207
Storage: 4C DNF
@
Purpose: To deliver siRNA into animal tissues by local or systemic administration in mice and then efficiently introducing it into cells.
component: This kit is intended for 10 times of administration.
1. Prefilled syringe (filled with ''AteloGene® '')
Each syringe is for 5 times of administration - 600 ul x 2 syringes
2. 10 x siRNA buffer - 3mL x 1 bottle
3. Sterilized water3mL x 1 bottle
4. Microtube - 2 mL x 2 tubes
5. Disposable syringe - 1 mL ~ 2 syringes
6. 18G needle (for ejection and suction) - 4 needles
7. 26G needle (for injection) - 2 needles
Instruction manual - 1 leaflet

Other:

 Background 
RNA interference (RNAi) is a mechanism where fragments of double-strand ribonucleic acid (dsRNA) interfere with the expression of a specific gene whose sequence is complementary to the dsRNA. Recently, RNAi medicines, which inhibit theexpression of genes responsible for diseases, have been studied activitely. However, the delivery of siRNA in vivo has become a big issue as siRNA is unstable in vivo. AteloGene® consists of a system mediated by atelocollagen, a solubilized collagen obtained by protease treatment. Atelogene transfects si RNA in vivo efficiently and safety in either local or systemic administration.
 Principle 
When mixed with synthetic siRNA at an appropriate concentration and ratio, atelocollagen, whichis a major component of AteloGene® forms a complex appropriate for administration into the body. siRNA that is prepared into a complex with atelocollagen is efficiently delivered in vivo and introduced into the cells
 Feature and advantages 
Immediate administration to experimental animals by simple mixing the synthetic siRNA with AteloGene®
Efficient in vivo transfection of siRNA.
Effect of RNAi of preventing degradation by RNase persists for a long time.
AteloGene® has no toxicity, and its main component, atelocollagen, demonstrates high biological compatibility.
It is possible to choose AteloGene® Local Use for local administration or AteloGene® Systemic Use for systemic administration by injection to the tail vein.
Since AteloGene® Local Use for local administration is gelated in the body, siRNA is securely kept at the administration site
Since AteloGene® Systemic Use for systemic administration is not gelated in the bodybut circulated in the blood after injection into the tail vein, siRNA is efficiently delivered to the whole body.




 IMAGE1





 IMAGE2





 IMAGE3





 IMAGE4



Procedures The method of preparing a mixture of "AteloGene" & siRNA is common to local and systemic administration. Please refer to the attached instruction manual in the kit for details of following operating procedures. 1)Preparation of "AteloGene" uPour the whole amount of "AteloGene" from the prefilled syringe into a microtube, and keep it on cooling device. 2)Preparation of siRNA solution Prepare 600 L of 5-10 ?M or 20-40 M siRNA solutions in the case of local or systemic administration, respectively. Keep the prepared solution cold. 3)Preparation of "AteloGene" & siRNA mixed solution. While cooling it on cooling device, gently pour the siRNA solution [in 2) above] on "AteloGene" [in 1) above], and prepare the "AteloGene" & siRNA mixture by tumbling, rotating and mixing them. 4) Removing bubbles and preparation for administration Centrifuge the "AteloGene" & siRNA mixture [in 3) above] to remove bubbles. Suck the mixture into a disposable syringe.

 IMAGE5





 IMAGE6





Reference:

[Local adiministration / Cancer research]
•  Deng Q. et al., Hepatology.(2013)
•  Endo H. et al., Carcinogenesis.34(3):560-569.(2013)
•  Fujiwara-Okada Y. et al., Br J Cancer.108(4):836-847.(2013)
•  Kabuta T. etal., J Biol Chem. (2013)
•  Nomura T. et al., Mol Cancer.12:27. (2013)
•  Takeuchi A. et al., Cancer Immunol Immunother.62(3):517-527. (2013)
•  Yamaki T. et al., Sci Rep.3:1160. (2013)
•  Kawamura M. et al., Cell Death Differ.19(1):170-179. (2012)
•  Kim BC. et al., EMBO J. 31(22):4289-4303. (2012)
•  Koike K. et al., Curr Cancer Drug Targets.12(7):847-856. (2012)
•  Okazaki T. et al., Cancer Lett.323(2):199-207. (2012)
•  El Sayed SM. et al., Cancer Gene Ther.19(1):1-18. (2012)
•  Shimada K. et al., Clin Cancer Res.18(19):5247-5255. (2012)
•  Sudo H. et al., Cancer Sci.103(2):203-209. (2012)
•  Ushida H. et al., J Urol.187(5):1876-1881. (2012)
•  Yamaguchi T. et al., Cancer Cell.21(3):348-361. (2012)
•  Yamato I. et al., Cancer Res.72(18):4829-4839 (2012)
•  Andradas C. et al., Oncogene.30(2):245-252. (2011)
•  Arai A. et al., Cancer Res.71(13):4598-4607. (2011)
•  Hashimoto A. et al., PLoS One.6(8):e23359. (2011)
•  Kobayashi T. et al., Clin Exp Metastasis.28(4):367-376. (2011)
•  Lorente M. et al., Cell Death Differ.18(6):959-973. (2011)
•  Matsuyama H. et al., Blood.118(26):6881-6892 (2011)
•  Oh BY. et al., World J Gastroenterol.17(20):2563-2571. (2011)
•  Shigematsu S. et al., Exp Cell Res.317(13):1851-1859. (2011)
•  Takei Y. et al., Cancer Res.71(4):1442-1453. (2011)
•  Takigami I. et al., Int J Cancer.128(1):216-226. (2011)
•  Tasaki M. et al., Br J Cancer.104(4):700-706. (2011)
•  Tomita S. et al., Cancer Sci.102(1):57-63. (2011)
•  Tsuruta T. et al., Cancer Res.71(20):6450-6462. (2011)
•  Vara D. et al., Cell Death Differ.18(7):1099-1111. (2011)
•  Zeng Y. et al., J Biol Chem.286(16):13985-13994. (2011)
•  Cheng L. et al., Oncogene.29(42):5700-5711. (2010)
•  Forootan SS. et al., Int J Oncol.36(1):69-76. (2010)
•  He L. et al., J Clin Invest.120(6):2094-2108. (2010)
•  Liu CJ. et al., Cancer Res.70(4):1635-1644. (2010)
•  Marsaud V. et al., Mol Cancer.9:103. (2010)
•  Nagano A. et al., Int J Cancer.126(12):2790-2798.(2010)
•  Satow R. et al., Clin Cancer Res 16(9):2518-2528.(2010)
•  Shitashige M. et al., Cancer Res.70(12):5024-5033. (2010)
•  Sudo H. et al., Genomics. 95(4):210-216. (2010)
•  Tanooka H. et al., Cancer Gene Ther.17(1):1-10. (2010)
•  Ashihara E. et al., Clin Cancer Res.15(8):2731-2738. (2009)
•  Lorente M. et al., Glia.57(13):1374-1385.(2009)
•  Mashima T. et al., Oncogene.28(1):9-19.(2009)
•  Shimada K. et al., Cancer Res.69(7):3157-3164.,(2009)
•  Shimada K. et al., Cancer Sci.100(7):1248-1254.(2009)
•  Yamaguchi U. et al., Cancer Sci.100(12):2268-2274.(2009)
•  Bernard-Pierrot I. et al., Cancer Res.68(17):7165-7175.(2008)
•  Honma K. et al., Nat Med.14(9):939-948.(2008)
•  Iwaki K. et al., Int J Cancer.122(3):658-663.(2008)
•  Migita T. et al., Cancer Res.68(20):8547-8554.(2008)
•  Shirasaki T. et al., BMC Cancer.8:348.(2008)
•  Ueno Y. et al., Int J Cancer.123(2):340-347.(2008)
•  Yamato K. et al., Cancer Gene Ther.15(3):140-153.(2008)
•  Yu D. et al., Cancer Sci.99(4):810-815.(2008)
•  Kokuryo T. et al., Cancer Res.67(20):9637-9642.(2007)
•  Nakazawa K. et al., Cancer.109(5):993-1002.(2007)
•  Tazawa H. et al., Proc Natl Acad Sci U S A.104(39):15472-15477.(2007)
•  Yamashita M. et al., Int J Cancer.120(10):2243-2250.(2007)
•  Fujii T. et al., Int J Oncol.29(3):541-548.(2006)
•  Nozawa H. et al., Cancer Sci.97(10):1115-1124.(2006)
•  Takei Y. et al., Cancer.107(4):864-873(2006)
•  Kuroda M. et al., Br J Cancer.92(2):290-293.(2005)
•  Takei Y. et al., Int J Cancer.114(3):490-497.(2005)
•  Minakuchi Y. et al., Nucleic Acids Res.32(13):e109.(2004)
•  Takei Y. etal., Cancer Res.64(10):3365-3370.(2004)
•  Hirai K. et al., J Gene Med.5(11):951-957.(2003)
•  Takei Y. et al., J Biol Chem.277(26):23800-23806.(2002)
•  Takei Y. et al., Cancer Res.61(23):8486-8491.(2001)
[Local administration / Various research]
•  Kawakami E. et al., PLoS One.8(5):e64719. (2013)
•  Kawakami Y. et al., Lab Invest.?(2013)
•  Makino K. et al., J Immunol.?190(8):3905-3915. (2013)
•  Matsukawa R. et al., Am J Hypertens.?26 (1): 51-57. (2013)
•  Ando T. et al., PLoS One?7(12): e51744. (2012)
•  Distler A. et al., Ann Rheum Dis.72(9):1575-1580. (2012)
•  Horn A. et al., Ann Rheum Dis.?71:785-789. (2012)
•  Khodzhigorova A. et al., Ann Rheum Dis. (2012)
•  Liu S. et al., Immunol Cell Biol.?90(3):337-345. (2012)
•  Bellner L. et al., Mol Vis.?17:1144-1152. (2011)
•  Matsukawa R. et al., J Hypertens.29(9):1735-1742.(2011)
•  Toyooka T. et al., J Neurotrauma.28(4):607-618. (2011)
•  Watanabe M. et al., PLoS One.6(4):e19017. (2011)
•  Nakasa T. et al., J Cell Mol Med.14(10):2495-2505. (2010)
•  Yusuke O. et al., J CellSci.?122(Pt 24):4427-4438. (2009)
•  Nagata Y. et al., Arthritis Rheum.60(9):2677-2683. (2009)
•  Matoba T. et al., Neuropathology.28(3):286-294. (2008)
•  Banno H. et al., J Vasc Surg.?44(3):633-641. (2006)
•  Shinozaki K. et al., Cardiovasc Pharmacol.46(4):505-512. (2005)
•  Nakamura M. et al., Gene Ther.?11(10):838-846. (2004)
•  Ochiya T. et al., Curr Gene Ther.?1(1):31-52. (2001)
◊  2011 ARVO Annual Meeting
◊  Cancer Res. 2011 Jul 1;71(13):4598-607
◊  J Biol Chem. 2011 Apr 22;286(16):13985-94
◊  Cancer Sci.?2011 Jan;102(1):57-63
◊  Glia.?2009 Oct;57(13):1374-85
◊  Cancer Gene Ther.?2011 Sep 16
◊  Mol Cancer. 2010; 9: 103
 
>